March 2, 2020

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont:

On February 4, 2020, Horizon Therapeutics USA, Inc. ("Horizon") notified the Vermont Attorney General of the following new prescription drug, pursuant to 18 V.S.A. § 4637(b):

NDC#	Product Description	Date of Commercial Availability	WAC
75987-0130-15	TEPEZZA Intravenous Solution Reconstituted 500 MG	February 3, 2020	$ 14,900.00

Horizon hereby notifies the Attorney General of the additional information required, pursuant to 18 V.S.A §4637(c).

Statutory Requirement	Reporting Information
A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	TEPEZZA is the first and only FDA-approved medicine for the treatment of Thyroid Eye Disease (TED), a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation and facial disfigurement. Horizon's approach will focus on educating physicians about the disease state and TEPEZZA, providing education and support that simplifies the patient journey, and helping to facilitate access to TEPEZZA. TEPEZZA is a targeted biologic that addresses the underlying disease process, and its potential to significantly change the lives of people living with this rare and vision-threatening disease underscores the compelling value it offers. In addition to the value TEPEZZA brings to patients who previously had no meaningful options other than multiple eye surgeries, the pricing decision also reflects the significant investment made to develop and make an approved treatment available to a rare disease patient population. Horizon engaged in meaningful conversations with payors, as well as key members of the Thyroid Eye Disease community regarding this value in relation to pricing.
The estimated volume of patients who may be prescribed the drug	Horizon estimates an annual U.S. incidence of 15-20K patients eligible for TEPEZZA
Was the drug granted breakthrough therapy designation by the federal Food and Drug Administration (FDA) prior to final approval?	Yes

Statutory Requirement	Reporting Information
Did the drug receive a priority review by the federal Food and Drug Administration prior to final approval?	Yes
The date and price of acquisition if the drug was FDA prior to final approval not developed by the manufacturer	N/A

Thank you for your consideration.

Regards,

Elena Moraitis
Associate Director, Pricing & Contracting
Horizon Therapeutics USA, Inc.